{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T21:38:49Z","timestamp":1791754729166,"version":"4.3.4"},"reference-count":118,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2021,10,11]],"date-time":"2021-10-11T00:00:00Z","timestamp":1633910400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,10,11]],"date-time":"2021-10-11T00:00:00Z","timestamp":1633910400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Health and Labor Science Research Grant Program in Japan"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Li\u2013Fraumeni syndrome (LFS) is a hereditary tumor that exhibits autosomal dominant inheritance. LFS develops in individuals with a pathogenic germline variant of the cancer-suppressor gene,\n                    <jats:italic>TP53<\/jats:italic>\n                    (individuals with\n                    <jats:italic>TP53<\/jats:italic>\n                    pathogenic variant). The number of individuals with\n                    <jats:italic>TP53<\/jats:italic>\n                    pathogenic variant among the general population is said to be 1 in 500 to 20,000. Meanwhile, it is found in 1.6% (median value, range of 0\u20136.7%) of patients with pediatric cancer and 0.2% of adult patients with cancer. LFS is diagnosed by the presence of germline\n                    <jats:italic>TP53<\/jats:italic>\n                    pathogenic variants. However, patients can still be diagnosed with LFS even in the absence of a\n                    <jats:italic>TP53<\/jats:italic>\n                    pathogenic variant if the familial history of cancers fit the classic LFS diagnostic criteria. It is recommended that\n                    <jats:italic>TP53<\/jats:italic>\n                    genetic testing be promptly performed if LFS is suspected. Chompret criteria are widely used for the\n                    <jats:italic>TP53<\/jats:italic>\n                    genetic test. However, as there are a certain number of cases of LFS that do not fit the criteria, if LFS is suspected,\n                    <jats:italic>TP53<\/jats:italic>\n                    genetic testing should be performed regardless of the criteria. The probability of individuals with\n                    <jats:italic>TP53<\/jats:italic>\n                    pathogenic variant developing cancer in their lifetime (penetrance) is 75% for men and almost 100% for women. The LFS core tumors (breast cancer, osteosarcoma, soft tissue sarcoma, brain tumor, and adrenocortical cancer) constitute the majority of cases; however, various types of cancers, such as hematological malignancy, epithelial cancer, and pediatric cancers, such as neuroblastoma, can also develop. Furthermore, approximately half of the cases develop simultaneous or metachronous multiple cancers. The types of\n                    <jats:italic>TP53<\/jats:italic>\n                    pathogenic variants and factors that modify the functions of\n                    <jats:italic>TP53<\/jats:italic>\n                    have an impact on the clinical presentation, although there are currently no definitive findings. There is currently no cancer preventive agent for individuals with\n                    <jats:italic>TP53<\/jats:italic>\n                    pathogenic variant. Surgical treatments, such as risk-reducing bilateral mastectomy warrant further investigation. Theoretically, exposure to radiation could induce the onset of secondary cancer; therefore, imaging and treatments that use radiation should be avoided as much as possible. As a method to follow-up LFS, routine cancer surveillance comprising whole-body MRI scan, brain MRI scan, breast MRI scan, and abdominal ultrasonography (US) should be performed immediately after the diagnosis. However, the effectiveness of this surveillance is unknown, and there are problems, such as adverse events associated with a high rate of false positives, overdiagnosis, and sedation used during imaging as well as negative psychological impact. The detection rate of cancer through cancer surveillance is extremely high. Many cases are detected at an early stage, and treatments are low intensity; thus, cancer surveillance could contribute to an improvement in QOL, or at least, a reduction in complications associated with treatment. With the widespread use of genomic medicine, the diagnosis of LFS is unavoidable, and a comprehensive medical care system for LFS is necessary. Therefore, clinical trials that verify the feasibility and effectiveness of the program, comprising LFS registry, genetic counseling, and cancer surveillance, need to be prepared.\n                  <\/jats:p>","DOI":"10.1007\/s10147-021-02011-w","type":"journal-article","created":{"date-parts":[[2021,10,11]],"date-time":"2021-10-11T10:02:46Z","timestamp":1633946566000},"page":"2161-2178","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":72,"title":["Medical guidelines for Li\u2013Fraumeni syndrome 2019, version 1.1"],"prefix":"10.1007","volume":"26","author":[{"given":"Tadashi","family":"Kumamoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumito","family":"Yamazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiko","family":"Nakano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chieko","family":"Tamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shimon","family":"Tashiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyoshi","family":"Hattori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Nakagawara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukiko","family":"Tsunematsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,10,11]]},"reference":[{"key":"2011_CR1","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1158\/1078-0432.CCR-17-0702","volume":"23","author":"GM Brodeur","year":"2017","unstructured":"Brodeur GM, Nichols KE, Plon SE et al (2017) Pediatric cancer predisposition and surveillance: an overview, and a tribute to Alfred G. Knudson Jr. Clin Cancer Res 23:e1\u2013e5","journal-title":"Clin Cancer Res"},{"key":"2011_CR2","doi-asserted-by":"publisher","first-page":"e6","DOI":"10.1158\/1078-0432.CCR-17-0515","volume":"23","author":"M-LC Greer","year":"2017","unstructured":"Greer M-LC, Voss SD, States LJ (2017) Pediatric cancer predisposition imaging: focus on whole-body MRI. Clin Cancer Res 23:e6\u2013e13","journal-title":"Clin Cancer Res"},{"key":"2011_CR3","doi-asserted-by":"publisher","first-page":"e14","DOI":"10.1158\/1078-0432.CCR-17-0428","volume":"23","author":"CC Porter","year":"2017","unstructured":"Porter CC, Druley TE, Erez A et al (2017) Recommendations for surveillance for children with leukemia-predisposing conditions. Clin Cancer Res 23:e14\u2013e22","journal-title":"Clin Cancer Res"},{"key":"2011_CR4","doi-asserted-by":"publisher","first-page":"e23","DOI":"10.1158\/1078-0432.CCR-17-0465","volume":"23","author":"MF Walsh","year":"2017","unstructured":"Walsh MF, Chang VY, Kohlmann WK et al (2017) Recommendations for childhood cancer screening and surveillance in DNA repair disorders. Clin Cancer Res 23:e23\u2013e31","journal-title":"Clin Cancer Res"},{"key":"2011_CR5","doi-asserted-by":"publisher","first-page":"e32","DOI":"10.1158\/1078-0432.CCR-17-0574","volume":"23","author":"U Tabori","year":"2017","unstructured":"Tabori U, Hansford JR, Achatz MI et al (2017) Clinical management and tumor surveillance recommendations of inherited mismatch repair deficiency in childhood. Clin Cancer Res 23:e32\u2013e37","journal-title":"Clin Cancer Res"},{"key":"2011_CR6","doi-asserted-by":"publisher","first-page":"e38","DOI":"10.1158\/1078-0432.CCR-17-0408","volume":"23","author":"CP Kratz","year":"2017","unstructured":"Kratz CP, Achatz MI, Brugi\u00e8res L et al (2017) Cancer screening recommendations for individuals with Li\u2013Fraumeni syndrome. Clin Cancer Res 23:e38\u2013e45","journal-title":"Clin Cancer Res"},{"key":"2011_CR7","doi-asserted-by":"publisher","first-page":"e46","DOI":"10.1158\/1078-0432.CCR-17-0589","volume":"23","author":"DGR Evans","year":"2017","unstructured":"Evans DGR, Salvador H, Chang VY et al (2017) Cancer and central nervous system tumor surveillance in pediatric neurofibromatosis 1. Clin Cancer Res 23:e46\u2013e53","journal-title":"Clin Cancer Res"},{"key":"2011_CR8","doi-asserted-by":"publisher","first-page":"e54","DOI":"10.1158\/1078-0432.CCR-17-0590","volume":"23","author":"DGR Evans","year":"2017","unstructured":"Evans DGR, Salvador H, Chang VY et al (2017) Cancer and central nervous system tumor surveillance in pediatric neurofibromatosis 2 and related disorders. Clin Cancer Res 23:e54\u2013e61","journal-title":"Clin Cancer Res"},{"key":"2011_CR9","doi-asserted-by":"publisher","first-page":"e62","DOI":"10.1158\/1078-0432.CCR-17-0595","volume":"23","author":"WD Foulkes","year":"2017","unstructured":"Foulkes WD, Kamihara J, Evans DGR et al (2017) Cancer surveillance in Gorlin syndrome and rhabdoid tumor predisposition syndrome. Clin Cancer Res 23:e62\u2013e67","journal-title":"Clin Cancer Res"},{"key":"2011_CR10","doi-asserted-by":"publisher","first-page":"e68","DOI":"10.1158\/1078-0432.CCR-17-0547","volume":"23","author":"SP Rednam","year":"2017","unstructured":"Rednam SP, Erez A, Druker H et al (2017) Von Hippel-Lindau and hereditary pheochromocytoma\/paraganglioma syndromes: clinical features, genetics, and surveillance recommendations in childhood. Clin Cancer Res 23:e68\u2013e75","journal-title":"Clin Cancer Res"},{"key":"2011_CR11","doi-asserted-by":"publisher","first-page":"e76","DOI":"10.1158\/1078-0432.CCR-17-0629","volume":"23","author":"KAP Schultz","year":"2017","unstructured":"Schultz KAP, Rednam SP, Kamihara J et al (2017) PTEN, DICER1, FH, and their associated tumor susceptibility syndromes: clinical features, genetics, and surveillance recommendations in childhood. Clin Cancer Res 23:e76\u2013e82","journal-title":"Clin Cancer Res"},{"key":"2011_CR12","doi-asserted-by":"publisher","first-page":"e83","DOI":"10.1158\/1078-0432.CCR-17-0631","volume":"23","author":"A Villani","year":"2017","unstructured":"Villani A, Greer MC, Kalish JM et al (2017) Recommendations for cancer surveillance in individuals with RASopathies and other rare genetic conditions with increased cancer risk. Clin Cancer Res 23:e83\u2013e90","journal-title":"Clin Cancer Res"},{"key":"2011_CR13","doi-asserted-by":"publisher","first-page":"e91","DOI":"10.1158\/1078-0432.CCR-17-0834","volume":"23","author":"H Druker","year":"2017","unstructured":"Druker H, Zelley K, McGee RB et al (2017) Genetic counselor recommendations for cancer predisposition evaluation and surveillance in the pediatric oncology patient. Clin Cancer Res 23:e91\u2013e97","journal-title":"Clin Cancer Res"},{"key":"2011_CR14","doi-asserted-by":"publisher","first-page":"e98","DOI":"10.1158\/1078-0432.CCR-17-0652","volume":"23","author":"J Kamihara","year":"2017","unstructured":"Kamihara J, Bourdeaut F, Foulkes WD et al (2017) Retinoblastoma and neuroblastoma predisposition and surveillance. Clin Cancer Res 23:e98\u2013e106","journal-title":"Clin Cancer Res"},{"key":"2011_CR15","doi-asserted-by":"publisher","first-page":"e107","DOI":"10.1158\/1078-0432.CCR-17-0790","volume":"23","author":"MI Achatz","year":"2017","unstructured":"Achatz MI, Porter CC, Brugieres L et al (2017) Cancer screening recommendations and clinical management of inherited gastrointestinal cancer syndromes in childhood. Clin Cancer Res 23:e107\u2013e114","journal-title":"Clin Cancer Res"},{"key":"2011_CR16","doi-asserted-by":"publisher","first-page":"e115","DOI":"10.1158\/1078-0432.CCR-17-0710","volume":"23","author":"JM Kalish","year":"2017","unstructured":"Kalish JM, Doros L, Helman LJ et al (2017) Surveillance recommendations for children with overgrowth syndromes and predisposition to Wilms tumors and hepatoblastoma. Clin Cancer Res 23:e115\u2013e122","journal-title":"Clin Cancer Res"},{"key":"2011_CR17","doi-asserted-by":"publisher","first-page":"e123","DOI":"10.1158\/1078-0432.CCR-17-0548","volume":"23","author":"JD Wasserman","year":"2017","unstructured":"Wasserman JD, Tomlinson GE, Druker H et al (2017) Multiple endocrine neoplasia and hyperparathyroid-jaw tumor syndromes: clinical features, genetics, and surveillance recommendations in childhood. Clin Cancer Res 23:e123\u2013e132","journal-title":"Clin Cancer Res"},{"key":"2011_CR18","first-page":"1365","volume":"43","author":"FP Li","year":"1969","unstructured":"Li FP, Fraumeni JF Jr (1969) Rhabdomyosarcoma in children: epidemiologic study and identification of a familial cancer syndrome. J Natl Cancer Inst 43:1365\u20131373","journal-title":"J Natl Cancer Inst"},{"key":"2011_CR19","first-page":"5358","volume":"48","author":"FP Li","year":"1988","unstructured":"Li FP, Fraumeni JF Jr, Mulvihill JJ et al (1988) A cancer family syndrome in twenty-four kindreds. Cancer Res 48:5358\u20135362","journal-title":"Cancer Res"},{"key":"2011_CR20","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1126\/science.1978757","volume":"250","author":"D Malkin","year":"1990","unstructured":"Malkin D, Li FP, Strong LC et al (1990) Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 250:1233\u20131238","journal-title":"Science"},{"key":"2011_CR21","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1200\/JCO.2008.16.6959","volume":"27","author":"KD Gonzalez","year":"2009","unstructured":"Gonzalez KD, Noltner KA, Buzin CH et al (2009) Beyond Li Fraumeni Syndrome: clinical characteristics of families with p53 germline mutations. J Clin Oncol 27:1250\u20131256","journal-title":"J Clin Oncol"},{"key":"2011_CR22","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1016\/S0140-6736(03)12856-5","volume":"361","author":"F Lalloo","year":"2003","unstructured":"Lalloo F, Varley J, Ellis D et al (2003) Prediction of pathogenic mutations in patients with early-onset breast cancer by family history. Lancet 361:1101\u20131102","journal-title":"Lancet"},{"key":"2011_CR23","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1002\/humu.23320","volume":"38","author":"KC de Andrade","year":"2017","unstructured":"de Andrade KC, Mirabello L, Stewart DR et al (2017) Higher-than-expected population prevalence of potentially pathogenic germline TP53 variants in individuals unselected for cancer history. Hum Mutat 38:1723\u20131730","journal-title":"Hum Mutat"},{"key":"2011_CR24","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/s10038-017-0347-1","volume":"63","author":"Y Yamaguchi-Kabata","year":"2018","unstructured":"Yamaguchi-Kabata Y, Yasuda J, Tanabe O et al (2018) Evaluation of reported pathogenic variants and their frequencies in a Japanese population based on a whole-genome reference panel of 2049 individuals. J Hum Genet 63:213\u2013230","journal-title":"J Hum Genet"},{"key":"2011_CR25","doi-asserted-by":"publisher","first-page":"2336","DOI":"10.1056\/NEJMoa1508054","volume":"373","author":"J Zhang","year":"2015","unstructured":"Zhang J, Walsh MF, Wu G et al (2015) Germline mutations in predisposition genes in pediatric cancer. N Engl J Med 373:2336\u20132346","journal-title":"N Engl J Med"},{"key":"2011_CR26","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/nature25480","volume":"555","author":"SN Grobner","year":"2018","unstructured":"Grobner SN, Worst BC, Weischenfeldt J et al (2018) The landscape of genomic alterations across childhood cancers. Nature 555:321\u2013327","journal-title":"Nature"},{"key":"2011_CR27","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1001\/jamaoncol.2015.5699","volume":"2","author":"DW Parsons","year":"2016","unstructured":"Parsons DW, Roy A, Yang Y et al (2016) Diagnostic yield of clinical tumor and germline whole-exome sequencing for children with solid tumors. JAMA Oncol 2:616\u2013624","journal-title":"JAMA Oncol"},{"key":"2011_CR28","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1001\/jamaoncol.2015.5689","volume":"2","author":"MH Harris","year":"2016","unstructured":"Harris MH, DuBois SG, Glade Bender JL et al (2016) Multicenter feasibility study of tumor molecular profiling to inform therapeutic decisions in advanced pediatric solid tumors: the individualized cancer therapy (iCat) study. JAMA Oncol 2:608\u2013615","journal-title":"JAMA Oncol"},{"key":"2011_CR29","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.ejca.2016.06.009","volume":"65","author":"BC Worst","year":"2016","unstructured":"Worst BC, van Tilburg CM, Balasubramanian GP et al (2016) Next-generation personalised medicine for high-risk paediatric cancer patients\u2014the INFORM pilot study. Eur J Cancer 65:91\u2013101","journal-title":"Eur J Cancer"},{"key":"2011_CR30","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1001\/jama.2015.10080","volume":"314","author":"RJ Mody","year":"2015","unstructured":"Mody RJ, Wu YM, Lonigro RJ et al (2015) Integrative clinical sequencing in the management of refractory or relapsed cancer in youth. JAMA 314:913\u2013925","journal-title":"JAMA"},{"key":"2011_CR31","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1001\/jamaoncol.2015.5208","volume":"2","author":"KA Schrader","year":"2016","unstructured":"Schrader KA, Cheng DT, Joseph V et al (2016) Germline variants in targeted tumor sequencing using matched normal DNA. JAMA Oncol 2:104\u2013111","journal-title":"JAMA Oncol"},{"key":"2011_CR32","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1136\/jmg.38.1.43","volume":"38","author":"A Chompret","year":"2001","unstructured":"Chompret A, Abel A, Stoppa-Lyonnet D et al (2001) Sensitivity and predictive value of criteria for p53 germline mutation screening. J Med Genet 38:43\u201347","journal-title":"J Med Genet"},{"key":"2011_CR33","doi-asserted-by":"crossref","unstructured":"Tinat J, Bougeard G, Baert-Desurmont S et al (2009) version of the Chompret criteria for Li\u2013Fraumeni syndrome. J Clin Oncol 27:e108\u2013109; author reply e10","DOI":"10.1200\/JCO.2009.22.7967"},{"key":"2011_CR34","doi-asserted-by":"publisher","first-page":"2345","DOI":"10.1200\/JCO.2014.59.5728","volume":"33","author":"G Bougeard","year":"2015","unstructured":"Bougeard G, Renaux-Petel M, Flaman JM et al (2015) Revisiting Li\u2013Fraumeni Syndrome from TP53 mutation carriers. J Clin Oncol 33:2345\u20132352","journal-title":"J Clin Oncol"},{"key":"2011_CR35","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1200\/JCO.2013.52.6863","volume":"33","author":"JD Wasserman","year":"2015","unstructured":"Wasserman JD, Novokmet A, Eichler-Jonsson C et al (2015) Prevalence and functional consequence of TP53 mutations in pediatric adrenocortical carcinoma: a children\u2019s oncology group study. J Clin Oncol 33:602\u2013609","journal-title":"J Clin Oncol"},{"key":"2011_CR36","doi-asserted-by":"publisher","first-page":"E119","DOI":"10.1210\/jc.2012-2198","volume":"98","author":"VM Raymond","year":"2013","unstructured":"Raymond VM, Else T, Everett JN et al (2013) Prevalence of germline TP53 mutations in a prospective series of unselected patients with adrenocortical carcinoma. J Clin Endocrinol Metab 98:E119\u2013E125","journal-title":"J Clin Endocrinol Metab"},{"key":"2011_CR37","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1055\/s-2005-861373","volume":"37","author":"F Sandrini","year":"2005","unstructured":"Sandrini F, Villani DP, Tucci S, Moreira AC, de Castro M, Elias LL (2005) Inheritance of R337H p53 gene mutation in children with sporadic adrenocortical tumor. Horm Metab Res 37:231\u2013235","journal-title":"Horm Metab Res"},{"key":"2011_CR38","doi-asserted-by":"publisher","first-page":"6302","DOI":"10.1038\/ncomms7302","volume":"6","author":"EM Pinto","year":"2015","unstructured":"Pinto EM, Chen X, Easton J et al (2015) Genomic landscape of paediatric adrenocortical tumours. Nat Commun 6:6302","journal-title":"Nat Commun"},{"key":"2011_CR39","doi-asserted-by":"publisher","first-page":"E476","DOI":"10.1210\/jc.2011-1982","volume":"97","author":"LJ Herrmann","year":"2012","unstructured":"Herrmann LJ, Heinze B, Fassnacht M et al (2012) TP53 germline mutations in adult patients with adrenocortical carcinoma. J Clin Endocrinol Metab 97:E476\u2013E485","journal-title":"J Clin Endocrinol Metab"},{"key":"2011_CR40","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1086\/302575","volume":"65","author":"JM Varley","year":"1999","unstructured":"Varley JM, McGown G, Thorncroft M et al (1999) Are there low-penetrance TP53 alleles? Evidence from childhood adrenocortical tumors. Am J Hum Genet 65:995\u20131006","journal-title":"Am J Hum Genet"},{"key":"2011_CR41","doi-asserted-by":"publisher","first-page":"3150","DOI":"10.1002\/cncr.30703","volume":"123","author":"MJ Mastellaro","year":"2017","unstructured":"Mastellaro MJ, Seidinger AL, Kang G et al (2017) Contribution of the TP53 R337H mutation to the cancer burden in southern Brazil: insights from the study of 55 families of children with adrenocortical tumors. Cancer 123:3150\u20133158","journal-title":"Cancer"},{"key":"2011_CR42","doi-asserted-by":"publisher","first-page":"2228","DOI":"10.1002\/cncr.25826","volume":"117","author":"AL Seidinger","year":"2011","unstructured":"Seidinger AL, Mastellaro MJ, Paschoal Fortes F et al (2011) Association of the highly prevalent TP53 R337H mutation with pediatric choroid plexus carcinoma and osteosarcoma in southeast Brazil. Cancer 117:2228\u20132235","journal-title":"Cancer"},{"key":"2011_CR43","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0018015","volume":"6","author":"G Custodio","year":"2011","unstructured":"Custodio G, Taques GR, Figueiredo BC et al (2011) Increased incidence of choroid plexus carcinoma due to the germline TP53 R337H mutation in southern Brazil. PLoS One 6:e18015","journal-title":"PLoS One"},{"key":"2011_CR44","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1002\/pbc.23349","volume":"58","author":"AE Gozali","year":"2012","unstructured":"Gozali AE, Britt B, Shane L et al (2012) Choroid plexus tumors; management, outcome, and association with the Li\u2013Fraumeni syndrome: the Children\u2019s Hospital Los Angeles (CHLA) experience, 1991\u20132010. Pediatr Blood Cancer 58:905\u2013909","journal-title":"Pediatr Blood Cancer"},{"key":"2011_CR45","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1200\/JCO.2009.26.8169","volume":"28","author":"U Tabori","year":"2010","unstructured":"Tabori U, Shlien A, Baskin B et al (2010) TP53 alterations determine clinical subgroups and survival of patients with choroid plexus tumors. J Clin Oncol 28:1995\u20132001","journal-title":"J Clin Oncol"},{"key":"2011_CR46","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1002\/cncr.28507","volume":"120","author":"S Hettmer","year":"2014","unstructured":"Hettmer S, Archer NM, Somers GR et al (2014) Anaplastic rhabdomyosarcoma in TP53 germline mutation carriers. Cancer 120:1068\u20131075","journal-title":"Cancer"},{"key":"2011_CR47","doi-asserted-by":"publisher","first-page":"4083","DOI":"10.1038\/s41467-018-06581-8","volume":"9","author":"Y Momozawa","year":"2018","unstructured":"Momozawa Y, Iwasaki Y, Parsons MT et al (2018) Germline pathogenic variants of 11 breast cancer genes in 7,051 Japanese patients and 11,241 controls. Nat Commun 9:4083","journal-title":"Nat Commun"},{"key":"2011_CR48","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1007\/s10549-017-4356-8","volume":"165","author":"XR Yang","year":"2017","unstructured":"Yang XR, Devi BCR, Sung H et al (2017) Prevalence and spectrum of germline rare variants in BRCA1\/2 and PALB2 among breast cancer cases in Sarawak, Malaysia. Breast Cancer Res Treat 165:687\u2013697","journal-title":"Breast Cancer Res Treat"},{"key":"2011_CR49","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1002\/ijc.30771","volume":"141","author":"S Lolas Hamameh","year":"2017","unstructured":"Lolas Hamameh S, Renbaum P, Kamal L et al (2017) Genomic analysis of inherited breast cancer among Palestinian women: genetic heterogeneity and a founder mutation in TP53. Int J Cancer 141:750\u2013756","journal-title":"Int J Cancer"},{"key":"2011_CR50","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1200\/JCO.2015.65.0747","volume":"34","author":"N Tung","year":"2016","unstructured":"Tung N, Lin NU, Kidd J et al (2016) Frequency of germline mutations in 25 cancer susceptibility genes in a sequential series of patients with breast cancer. J Clin Oncol 34:1460\u20131468","journal-title":"J Clin Oncol"},{"key":"2011_CR51","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/1897-4287-10-3","volume":"10","author":"MC Gomes","year":"2012","unstructured":"Gomes MC, Kotsopoulos J, de Almeida GL et al (2012) The R337H mutation in TP53 and breast cancer in Brazil. Hered Cancer Clin Pract 10:3","journal-title":"Hered Cancer Clin Pract"},{"key":"2011_CR52","first-page":"2984","volume":"52","author":"D Sidransky","year":"1992","unstructured":"Sidransky D, Tokino T, Helzlsouer K et al (1992) Inherited p53 gene mutations in breast cancer. Cancer Res 52:2984\u20132986","journal-title":"Cancer Res"},{"key":"2011_CR53","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1007\/s10549-017-4291-8","volume":"164","author":"SK Rummel","year":"2017","unstructured":"Rummel SK, Lovejoy L, Shriver CD, Ellsworth RE (2017) Contribution of germline mutations in cancer predisposition genes to tumor etiology in young women diagnosed with invasive breast cancer. Breast Cancer Res Treat 164:593\u2013601","journal-title":"Breast Cancer Res Treat"},{"key":"2011_CR54","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1111\/tbj.12308","volume":"20","author":"J Giacomazzi","year":"2014","unstructured":"Giacomazzi J, Correia RL, Palmero EI et al (2014) The Brazilian founder mutation TP53 p.R337H is uncommon in Portuguese women diagnosed with breast cancer. Breast J 20:534\u2013546","journal-title":"Breast J"},{"key":"2011_CR55","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0057581","volume":"8","author":"DM Carraro","year":"2013","unstructured":"Carraro DM, Koike Folgueira MA, Garcia Lisboa BC et al (2013) Comprehensive analysis of BRCA1, BRCA2 and TP53 germline mutation and tumor characterization: a portrait of early-onset breast cancer in Brazil. PLoS One 8:e57581","journal-title":"PLoS One"},{"key":"2011_CR56","doi-asserted-by":"publisher","first-page":"4795","DOI":"10.1158\/0008-5472.CAN-09-0851","volume":"70","author":"J Mouchawar","year":"2010","unstructured":"Mouchawar J, Korch C, Byers T et al (2010) Population-based estimate of the contribution of TP53 mutations to subgroups of early-onset breast cancer: Australian Breast Cancer Family Study. Cancer Res 70:4795\u20134800","journal-title":"Cancer Res"},{"key":"2011_CR57","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1007\/s10689-009-9287-z","volume":"8","author":"OM Ginsburg","year":"2009","unstructured":"Ginsburg OM, Akbari MR, Aziz Z et al (2009) The prevalence of germ-line TP53 mutations in women diagnosed with breast cancer before age 30. Fam Cancer 8:563\u2013567","journal-title":"Fam Cancer"},{"key":"2011_CR58","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0125571","volume":"10","author":"X Yang","year":"2015","unstructured":"Yang X, Wu J, Lu J et al (2015) Identification of a comprehensive spectrum of genetic factors for hereditary breast cancer in a Chinese population by next-generation sequencing. PLoS One 10:e0125571","journal-title":"PLoS One"},{"key":"2011_CR59","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1001\/jama.295.12.1379","volume":"295","author":"T Walsh","year":"2006","unstructured":"Walsh T, Casadei S, Coats KH et al (2006) Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer. JAMA 295:1379\u20131388","journal-title":"JAMA"},{"key":"2011_CR60","doi-asserted-by":"publisher","first-page":"3673","DOI":"10.1002\/cncr.30248","volume":"122","author":"PL Mai","year":"2016","unstructured":"Mai PL, Best AF, Peters JA et al (2016) Risks of first and subsequent cancers among TP53 mutation carriers in the National Cancer Institute Li-Fraumeni syndrome cohort. Cancer 122:3673\u20133681","journal-title":"Cancer"},{"key":"2011_CR61","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1086\/374567","volume":"72","author":"SJ Hwang","year":"2003","unstructured":"Hwang SJ, Lozano G, Amos CI, Strong LC (2003) Germline p53 mutations in a cohort with childhood sarcoma: sex differences in cancer risk. Am J Hum Genet 72:975\u2013983","journal-title":"Am J Hum Genet"},{"key":"2011_CR62","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1136\/jmg.2009.073429","volume":"47","author":"MW Ruijs","year":"2010","unstructured":"Ruijs MW, Verhoef S, Rookus MA et al (2010) TP53 germline mutation testing in 180 families suspected of Li\u2013Fraumeni syndrome: mutation detection rate and relative frequency of cancers in different familial phenotypes. J Med Genet 47:421\u2013428","journal-title":"J Med Genet"},{"key":"2011_CR63","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1007\/s00439-011-0957-1","volume":"129","author":"CC Wu","year":"2011","unstructured":"Wu CC, Krahe R, Lozano G et al (2011) Joint effects of germ-line TP53 mutation, MDM2 SNP309, and gender on cancer risk in family studies of Li\u2013Fraumeni syndrome. Hum Genet 129:663\u2013673","journal-title":"Hum Genet"},{"key":"2011_CR64","doi-asserted-by":"publisher","first-page":"8287","DOI":"10.1158\/0008-5472.CAN-05-4247","volume":"66","author":"CC Wu","year":"2006","unstructured":"Wu CC, Shete S, Amos CI, Strong LC (2006) Joint effects of germ-line p53 mutation and sex on cancer risk in Li\u2013Fraumeni syndrome. Cancer Res 66:8287\u20138292","journal-title":"Cancer Res"},{"key":"2011_CR65","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1002\/cncr.26390","volume":"118","author":"S Ognjanovic","year":"2012","unstructured":"Ognjanovic S, Olivier M, Bergemann TL, Hainaut P (2012) Sarcomas in TP53 germline mutation carriers: a review of the IARC TP53 database. Cancer 118:1387\u20131396","journal-title":"Cancer"},{"key":"2011_CR66","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s00439-005-0016-x","volume":"118","author":"BW Brown","year":"2005","unstructured":"Brown BW, Costello TJ, Hwang SJ, Strong LC (2005) Generation or birth cohort effect on cancer risk in Li\u2013Fraumeni syndrome. Hum Genet 118:489\u2013498","journal-title":"Hum Genet"},{"key":"2011_CR67","doi-asserted-by":"publisher","first-page":"2619","DOI":"10.1200\/JCO.2012.46.3711","volume":"31","author":"G Custodio","year":"2013","unstructured":"Custodio G, Parise GA, Kiesel Filho N et al (2013) Impact of neonatal screening and surveillance for the TP53 R337H mutation on early detection of childhood adrenocortical tumors. J Clin Oncol 31:2619\u20132626","journal-title":"J Clin Oncol"},{"key":"2011_CR68","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s10689-013-9667-2","volume":"13","author":"M Renaux-Petel","year":"2014","unstructured":"Renaux-Petel M, Sesboue R, Baert-Desurmont S et al (2014) The MDM2 285G\u2013309G haplotype is associated with an earlier age of tumour onset in patients with Li\u2013Fraumeni syndrome. Fam Cancer 13:127\u2013130","journal-title":"Fam Cancer"},{"key":"2011_CR69","first-page":"6643","volume":"63","author":"M Olivier","year":"2003","unstructured":"Olivier M, Goldgar DE, Sodha N et al (2003) Li\u2013Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype. Cancer Res 63:6643\u20136650","journal-title":"Cancer Res"},{"key":"2011_CR70","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/j.tips.2017.07.004","volume":"38","author":"R Zhou","year":"2017","unstructured":"Zhou R, Xu A, Gingold J, Strong LC, Zhao R, Lee DF (2017) Li\u2013Fraumeni syndrome disease model: a platform to develop precision cancer therapy targeting oncogenic p53. Trends Pharmacol Sci 38:908\u2013927","journal-title":"Trends Pharmacol Sci"},{"key":"2011_CR71","doi-asserted-by":"publisher","first-page":"2331","DOI":"10.1200\/JCO.2015.61.5757","volume":"33","author":"KE Nichols","year":"2015","unstructured":"Nichols KE, Malkin D (2015) Genotype versus phenotype: the Yin and Yang of germline TP53 mutations in Li\u2013Fraumeni Syndrome. J Clin Oncol 33:2331\u20132333","journal-title":"J Clin Oncol"},{"key":"2011_CR72","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1016\/j.cell.2004.11.022","volume":"119","author":"GL Bond","year":"2004","unstructured":"Bond GL, Hu W, Bond EE et al (2004) A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 119:591\u2013602","journal-title":"Cell"},{"key":"2011_CR73","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1136\/jmg.2005.037952","volume":"43","author":"G Bougeard","year":"2006","unstructured":"Bougeard G, Baert-Desurmont S, Tournier I et al (2006) Impact of the MDM2 SNP309 and p53 Arg72Pro polymorphism on age of tumour onset in Li\u2013Fraumeni syndrome. J Med Genet 43:531\u2013533","journal-title":"J Med Genet"},{"key":"2011_CR74","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1093\/carcin\/bgt381","volume":"35","author":"C Sagne","year":"2014","unstructured":"Sagne C, Marcel V, Bota M et al (2014) Age at cancer onset in germline TP53 mutation carriers: association with polymorphisms in predicted G-quadruplex structures. Carcinogenesis 35:807\u2013815","journal-title":"Carcinogenesis"},{"key":"2011_CR75","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1038\/sj.onc.1207305","volume":"23","author":"F Gemignani","year":"2004","unstructured":"Gemignani F, Moreno V, Landi S et al (2004) A TP53 polymorphism is associated with increased risk of colorectal cancer and with reduced levels of TP53 mRNA. Oncogene 23:1954\u20131956","journal-title":"Oncogene"},{"key":"2011_CR76","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1158\/0008-5472.CAN-06-3682","volume":"67","author":"U Tabori","year":"2007","unstructured":"Tabori U, Nanda S, Druker H, Lees J, Malkin D (2007) Younger age of cancer initiation is associated with shorter telomere length in Li\u2013Fraumeni syndrome. Cancer Res 67:1415\u20131418","journal-title":"Cancer Res"},{"key":"2011_CR77","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1002\/humu.23025","volume":"37","author":"B Id Said","year":"2016","unstructured":"Id Said B, Kim H, Tran J, Novokmet A, Malkin D (2016) Super-transactivation TP53 variant in the germline of a family with Li\u2013Fraumeni syndrome. Hum Mutat 37:889\u2013892","journal-title":"Hum Mutat"},{"issue":"30","key":"2011_CR78","doi-asserted-by":"publisher","first-page":"3697","DOI":"10.1200\/JCO.2016.67.6940","volume":"34","author":"N Samuel","year":"2016","unstructured":"Samuel N, Wilson G, Lemire M et al (2016) Genome-wide DNA methylation analysis reveals epigenetic dysregulation of microRNA-34A in TP53-associated cancer susceptibility. J Clin Oncol 34(30):3697\u20133704","journal-title":"J Clin Oncol"},{"key":"2011_CR79","doi-asserted-by":"publisher","first-page":"49611","DOI":"10.18632\/oncotarget.10417","volume":"7","author":"N Samuel","year":"2016","unstructured":"Samuel N, Wilson G, Id Said B et al (2016) Transcriptome-wide characterization of the endogenous miR-34A-p53 tumor suppressor network. Oncotarget 7:49611\u201349622","journal-title":"Oncotarget"},{"key":"2011_CR80","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1200\/JCO.2017.75.5215","volume":"36","author":"M Qian","year":"2018","unstructured":"Qian M, Cao X, Devidas M et al (2018) TP53 germline variations influence the predisposition and prognosis of B-cell acute lymphoblastic leukemia in children. J Clin Oncol 36:591\u2013599","journal-title":"J Clin Oncol"},{"key":"2011_CR81","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/S1470-2045(11)70119-X","volume":"12","author":"A Villani","year":"2011","unstructured":"Villani A, Tabori U, Schiffman J et al (2011) Biochemical and imaging surveillance in germline TP53 mutation carriers with Li\u2013Fraumeni syndrome: a prospective observational study. Lancet Oncol 12:559\u2013567","journal-title":"Lancet Oncol"},{"key":"2011_CR82","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1016\/S1470-2045(16)30249-2","volume":"17","author":"A Villani","year":"2016","unstructured":"Villani A, Shore A, Wasserman JD et al (2016) Biochemical and imaging surveillance in germline TP53 mutation carriers with Li\u2013Fraumeni syndrome: 11 year follow-up of a prospective observational study. Lancet Oncol 17:1295\u20131305","journal-title":"Lancet Oncol"},{"key":"2011_CR83","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1001\/jamaoncol.2017.1968","volume":"3","author":"ML Ballinger","year":"2017","unstructured":"Ballinger ML, Best A, Mai PL et al (2017) Baseline surveillance in Li\u2013Fraumeni syndrome using whole-body magnetic resonance imaging: a meta-analysis. JAMA Oncol 3:1634\u20131639","journal-title":"JAMA Oncol"},{"key":"2011_CR84","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1016\/S0140-6736(05)66481-1","volume":"365","author":"MO Leach","year":"2005","unstructured":"Leach MO, Boggis CR, Dixon AK et al (2005) Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS). Lancet 365:1769\u20131778","journal-title":"Lancet"},{"key":"2011_CR85","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1007\/s10689-017-0034-6","volume":"17","author":"J Bojadzieva","year":"2018","unstructured":"Bojadzieva J, Amini B, Day SF et al (2018) Whole body magnetic resonance imaging (WB-MRI) and brain MRI baseline surveillance in TP53 germline mutation carriers: experience from the Li\u2013Fraumeni Syndrome Education and Early Detection (LEAD) clinic. Fam Cancer 17:287\u2013294","journal-title":"Fam Cancer"},{"issue":"12","key":"2011_CR86","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1001\/jamaoncol.2017.1350","volume":"3","author":"PL Mai","year":"2017","unstructured":"Mai PL, Khincha PP, Loud JT et al (2017) Prevalence of cancer at baseline screening in the National Cancer Institute Li\u2013Fraumeni Syndrome Cohort. JAMA Oncol 3(12):1640\u20131645","journal-title":"JAMA Oncol"},{"key":"2011_CR87","doi-asserted-by":"crossref","unstructured":"O'Neill AF, Voss SD, Jagannathan JP et al (2018) Screening with whole-body magnetic resonance imaging in pediatric subjects with Li\u2013Fraumeni syndrome: a single institution pilot study. Pediatr Blood Cancer 65","DOI":"10.1002\/pbc.26822"},{"key":"2011_CR88","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s40644-018-0162-8","volume":"18","author":"D Paixao","year":"2018","unstructured":"Paixao D, Guimaraes MD, de Andrade KC, Nobrega AF, Chojniak R, Achatz MI (2018) Whole-body magnetic resonance imaging of Li\u2013Fraumeni syndrome patients: observations from a two rounds screening of Brazilian patients. Cancer Imaging 18:27","journal-title":"Cancer Imaging"},{"key":"2011_CR89","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/s10689-017-9965-1","volume":"16","author":"S Saya","year":"2017","unstructured":"Saya S, Killick E, Thomas S et al (2017) Baseline results from the UK SIGNIFY study: a whole-body MRI screening study in TP53 mutation carriers and matched controls. Fam Cancer 16:433\u2013440","journal-title":"Fam Cancer"},{"key":"2011_CR90","doi-asserted-by":"publisher","first-page":"2318","DOI":"10.1002\/cncr.21863","volume":"106","author":"M Kriege","year":"2006","unstructured":"Kriege M, Brekelmans CT, Boetes C et al (2006) Differences between first and subsequent rounds of the MRISC breast cancer screening program for women with a familial or genetic predisposition. Cancer 106:2318\u20132326","journal-title":"Cancer"},{"key":"2011_CR91","doi-asserted-by":"publisher","first-page":"38","DOI":"10.3389\/fonc.2015.00038","volume":"5","author":"ST Nogueira","year":"2015","unstructured":"Nogueira ST, Lima EN, Nobrega AF et al (2015) (18)F-FDG PET-CT for surveillance of Brazilian patients with Li\u2013Fraumeni syndrome. Front Oncol 5:38","journal-title":"Front Oncol"},{"key":"2011_CR92","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1001\/jama.299.11.1315","volume":"299","author":"S Masciari","year":"2008","unstructured":"Masciari S, Van den Abbeele AD, Diller LR et al (2008) F18-fluorodeoxyglucose-positron emission tomography\/computed tomography screening in Li\u2013Fraumeni syndrome. JAMA 299:1315\u20131319","journal-title":"JAMA"},{"key":"2011_CR93","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s10689-016-9935-z","volume":"16","author":"RC Andrade","year":"2017","unstructured":"Andrade RC, Dos Santos AC, de Aguirre Neto JC, Nevado J, Lapunzina P, Vargas FR (2017) TP53 and CDKN1A mutation analysis in families with Li\u2013Fraumeni and Li\u2013Fraumeni like syndromes. Fam Cancer 16:243\u2013248","journal-title":"Fam Cancer"},{"issue":"4","key":"2011_CR94","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1007\/s00401-019-02055-3","volume":"139","author":"BA Orr","year":"2019","unstructured":"Orr BA, Clay MR, Pinto EM, Kesserwan C (2019) An update on the central nervous system manifestations of Li\u2013Fraumeni syndrome. Acta Neuropathol 139(4):669\u2013687","journal-title":"Acta Neuropathol"},{"key":"2011_CR95","doi-asserted-by":"publisher","first-page":"a026062","DOI":"10.1101\/cshperspect.a026062","volume":"6","author":"BJ Aubrey","year":"2016","unstructured":"Aubrey BJ, Strasser A, Kelly GL (2016) Tumor-suppressor functions of the TP53 pathway. Cold Spring Harb Perspect Med 6:a026062","journal-title":"Cold Spring Harb Perspect Med"},{"key":"2011_CR96","first-page":"3013","volume":"35","author":"M Bahar","year":"2015","unstructured":"Bahar M, Kordes U, Tekautz T, Wolff J (2015) Radiation therapy for choroid plexus carcinoma patients with Li\u2013Fraumeni syndrome: advantageous or detrimental? Anticancer Res 35:3013\u20133017","journal-title":"Anticancer Res"},{"key":"2011_CR97","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1200\/JCO.2018.77.8589","volume":"36","author":"Z Wang","year":"2018","unstructured":"Wang Z, Wilson CL, Easton J et al (2018) Genetic risk for subsequent neoplasms among long-term survivors of childhood cancer. J Clin Oncol 36:2078\u20132087","journal-title":"J Clin Oncol"},{"key":"2011_CR98","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1148\/radiology.216.3.r00se45645","volume":"216","author":"DA Bluemke","year":"2000","unstructured":"Bluemke DA, Breiter SN (2000) Sedation procedures in MR imaging: safety, effectiveness, and nursing effect on examinations. Radiology 216:645\u2013652","journal-title":"Radiology"},{"key":"2011_CR99","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/s00247-011-2279-9","volume":"42","author":"J Bracken","year":"2012","unstructured":"Bracken J, Heaslip I, Ryan S (2012) Chloral hydrate sedation in radiology: retrospective audit of reduced dose. Pediatr Radiol 42:349\u2013354","journal-title":"Pediatr Radiol"},{"key":"2011_CR100","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1007\/s00247-014-3091-0","volume":"45","author":"J Delgado","year":"2015","unstructured":"Delgado J, Toro R, Rascovsky S et al (2015) Chloral hydrate in pediatric magnetic resonance imaging: evaluation of a 10-year sedation experience administered by radiologists. Pediatr Radiol 45:108\u2013114","journal-title":"Pediatr Radiol"},{"key":"2011_CR101","first-page":"111","volume":"16","author":"CM Glasier","year":"1995","unstructured":"Glasier CM, Stark JE, Brown R et al (1995) Rectal thiopental sodium for sedation of pediatric patients undergoing MR and other imaging studies. AJNR Am J Neuroradiol 16:111\u2013114","journal-title":"AJNR Am J Neuroradiol"},{"key":"2011_CR102","doi-asserted-by":"publisher","first-page":"639","DOI":"10.2214\/ajr.161.3.8352124","volume":"161","author":"SB Greenberg","year":"1993","unstructured":"Greenberg SB, Faerber EN, Aspinall CL et al (1993) High-dose chloral hydrate sedation for children undergoing MR imaging: safety and efficacy in relation to age. AJR Am J Roentgenol 161:639\u2013641","journal-title":"AJR Am J Roentgenol"},{"key":"2011_CR103","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1097\/00004728-199201000-00002","volume":"16","author":"AM Hubbard","year":"1992","unstructured":"Hubbard AM, Markowitz RI, Kimmel B et al (1992) Sedation for pediatric patients undergoing CT and MRI. J Comput Assist Tomogr 16:3\u20136","journal-title":"J Comput Assist Tomogr"},{"key":"2011_CR104","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/s12871-017-0431-2","volume":"17","author":"R Kang","year":"2017","unstructured":"Kang R, Shin YH, Gil NS et al (2017) A comparison of the use of propofol alone and propofol with midazolam for pediatric magnetic resonance imaging sedation - a retrospective cohort study. BMC Anesthesiol 17:138","journal-title":"BMC Anesthesiol"},{"key":"2011_CR105","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1016\/j.ajem.2012.01.009","volume":"30","author":"YJ Lee","year":"2012","unstructured":"Lee YJ, Kim DK, Kwak YH et al (2012) Analysis of the appropriate age and weight for pediatric patient sedation for magnetic resonance imaging. Am J Emerg Med 30:1189\u20131195","journal-title":"Am J Emerg Med"},{"key":"2011_CR106","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1093\/oxfordjournals.bja.a013586","volume":"84","author":"S Malviya","year":"2000","unstructured":"Malviya S, Voepel-Lewis T, Eldevik OP et al (2000) Sedation and general anaesthesia in children undergoing MRI and CT: adverse events and outcomes. Br J Anaesth 84:743\u2013748","journal-title":"Br J Anaesth"},{"key":"2011_CR107","doi-asserted-by":"publisher","first-page":"W574","DOI":"10.2214\/AJR.13.11580","volume":"202","author":"KP Mason","year":"2014","unstructured":"Mason KP, Turner DP, Houle TT et al (2014) Hemodynamic response to fluid management in children undergoing dexmedetomidine sedation for MRI. AJR Am J Roentgenol 202:W574\u2013W579","journal-title":"AJR Am J Roentgenol"},{"key":"2011_CR108","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1111\/j.1460-9592.2010.03299.x","volume":"20","author":"KP Mason","year":"2010","unstructured":"Mason KP, Zurakowski D, Zgleszewski S et al (2010) Incidence and predictors of hypertension during high-dose dexmedetomidine sedation for pediatric MRI. Paediatr Anaesth 20:516\u2013523","journal-title":"Paediatr Anaesth"},{"key":"2011_CR109","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1111\/j.1460-9592.1995.tb00330.x","volume":"5","author":"C Merola","year":"1995","unstructured":"Merola C, Albarracin C, Lebowitz P et al (1995) An audit of adverse events in children sedated with chloral hydrate or propofol during imaging studies. Paediatr Anaesth 5:375\u2013378","journal-title":"Paediatr Anaesth"},{"key":"2011_CR110","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1148\/radiol.2213010236","volume":"221","author":"MT Nguyen","year":"2001","unstructured":"Nguyen MT, Greenberg SB, Fitzhugh KR et al (2001) Pediatric imaging: sedation with an injection formulation modified for rectal administration. Radiology 221:760\u2013762","journal-title":"Radiology"},{"key":"2011_CR111","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1111\/j.1365-2710.1994.tb00680.x","volume":"19","author":"CL Ronchera-Oms","year":"1994","unstructured":"Ronchera-Oms CL, Casillas C, Marti-Bonmati L et al (1994) Oral chloral hydrate provides effective and safe sedation in paediatric magnetic resonance imaging. J Clin Pharm Ther 19:239\u2013243","journal-title":"J Clin Pharm Ther"},{"key":"2011_CR112","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1148\/radiol.2371041415","volume":"237","author":"PA Sanborn","year":"2005","unstructured":"Sanborn PA, Michna E, Zurakowski D et al (2005) Adverse cardiovascular and respiratory events during sedation of pediatric patients for imaging examinations. Radiology 237:288\u2013294","journal-title":"Radiology"},{"key":"2011_CR113","first-page":"181","volume":"88","author":"AP Jhaveri","year":"2015","unstructured":"Jhaveri AP, Bale A, Lovick N et al (2015) The benefit and burden of cancer screening in Li\u2013Fraumeni syndrome: a case report. Yale J Biol Med 88:181\u2013185","journal-title":"Yale J Biol Med"},{"key":"2011_CR114","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1007\/s10689-010-9368-z","volume":"9","author":"CR Lammens","year":"2010","unstructured":"Lammens CR, Bleiker EM, Aaronson NK et al (2010) Regular surveillance for Li\u2013Fraumeni syndrome: advice, adherence and perceived benefits. Fam Cancer 9:647\u2013654","journal-title":"Fam Cancer"},{"key":"2011_CR115","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/s10689-016-9964-7","volume":"16","author":"KA McBride","year":"2017","unstructured":"McBride KA, Ballinger ML, Schlub TE et al (2017) Psychosocial morbidity in TP53 mutation carriers: is whole-body cancer screening beneficial? Fam Cancer 16:423\u2013432","journal-title":"Fam Cancer"},{"key":"2011_CR116","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1038\/gim.2017.8","volume":"19","author":"J Ross","year":"2017","unstructured":"Ross J, Bojadzieva J, Peterson S et al (2017) The psychosocial effects of the Li\u2013Fraumeni Education and Early Detection (LEAD) program on individuals with Li\u2013Fraumeni syndrome. Genet Med 19:1064\u20131070","journal-title":"Genet Med"},{"issue":"10","key":"2011_CR117","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.27937","volume":"66","author":"Y Nakano","year":"2019","unstructured":"Nakano Y, Tsunematsu Y, Yamazaki F et al (2019) Pediatric patients with cancer predisposition in Japan: results of a questionnaire survey. Pediatr Blood Cancer 66(10):e27937","journal-title":"Pediatr Blood Cancer"},{"key":"2011_CR118","first-page":"594","volume":"73","author":"Y Tsunematsu","year":"2015","unstructured":"Tsunematsu Y (2015) Ethical legal and social implication of familial tumor. Nippon Rinsho 73:594\u2013600","journal-title":"Nippon Rinsho"}],"updated-by":[{"DOI":"10.1007\/s10147-021-02086-5","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2021,12,3]],"date-time":"2021-12-03T00:00:00Z","timestamp":1638489600000}}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-021-02011-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-021-02011-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-021-02011-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,10]],"date-time":"2023-11-10T18:44:35Z","timestamp":1699641875000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-021-02011-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,11]]},"references-count":118,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["2011"],"URL":"https:\/\/doi.org\/10.1007\/s10147-021-02011-w","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,11]]},"assertion":[{"value":"4 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 October 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2021","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s10147-021-02086-5","URL":"https:\/\/doi.org\/10.1007\/s10147-021-02086-5","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The members of the research group confirmed that they have no conflicts of interest relating to this guideline.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}